A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease

Trial Profile

A Two-part Study Exploring the Efficacy, Safety, and Pharmacodynamics of Acthar in Systemic Lupus Erythematosus Patients With a History of Persistently Active Disease

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Nov 2016

At a glance

  • Drugs Corticotropin (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Sponsors Mallinckrodt Inc.; Questcor Pharmaceuticals
  • Most Recent Events

    • 23 Nov 2016 Planned End Date changed from 1 Dec 2015 to 1 Jun 2017.
    • 23 Nov 2016 Planned primary completion date changed from 1 Jun 2015 to 1 May 2017.
    • 09 Nov 2015 Results published in a Malinckrodt Plc. Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top